Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
Medicus reallocates capital toward its CD228V oncology ADC and narrows SkinJect and Teverelix to select indications with mid-stage clinical studies.
Rhea-AI Summary
Medicus Pharma (MDCX) announced a strategic shift to become a precision oncology-led biotechnology company centered on its CD228V antibody-drug conjugate program.
CD228V, a second-generation ADC targeting melanotransferrin/CD228 in solid tumors, is now the Company’s principal priority, with initial development focused on establishing clinical proof-of-concept in melanoma, particularly relapsed or refractory disease. The program is backed by an active U.S. IND and a first-in-human Phase 1 trial (NCT06799533). Medicus is also refocusing SkinJect® on Gorlin syndrome, with FDA authorization to initiate SKNJCT-005, an NDA-enabling registrational Phase 2b study in patients with multiple BCCs. For Teverelix®, the Company plans to prioritize an approximately 126-patient Phase 2 acute urinary retention study and the PRECISION-E2 Phase 2a endometriosis trial while seeking partnerships in advanced prostate cancer.
Positive
- CD228V elevated to lead asset with active U.S. IND and ongoing Phase 1 study (NCT06799533)
- FDA authorized SKNJCT-005 registrational Phase 2b SkinJect study in Gorlin syndrome patients with multiple BCCs
- Teverelix development focused on ~126-patient Phase 2 AUR trial and PRECISION-E2 Phase 2a endometriosis study
- Company pursuing capital-efficient partnerships to advance SkinJect and Teverelix in advanced prostate cancer
Negative
- None.
News Explained
Medicus is directing resources toward CD228V, while partnership funding for SkinJect and Teverelix remains prospective and does not disclose ownership mechanics.
On
The stated structure is an internal shift of resources toward CD228V alongside potential outside partnerships for the other programs; the update names no partner, agreement terms, funding amount, or ownership mechanics.
As of
The material unresolved items are whether the proposed partnerships produce identified counterparties and disclosed terms, and how the stated capital concentration is reflected in subsequent program filings and study milestones.
Sources and calculations
- Medicus Pharma strategic update (2026-09-08)
- Medicus Pharma second-quarter 2026 fundamentals (2026-06-30)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $15,174,128 / ($6,983,441 / 91) = 197.7 days
Key Figures
- CD228V trial phase
- Phase 1
- First-in-human clinical study
- CD228V IND status
- Active U.S. IND
- CD228V development program
- SKNJCT-005 trial phase
- Phase 2b
- NDA-enabling registrational study in Gorlin syndrome
- SKNJCT-005 authorization
- FDA authorized initiation
- Gorlin syndrome patients with multiple BCCs
- Teverelix AUR study size
- approximately 126 patients
- Phase 2 acute urinary retention program
- PRECISION-E2 trial phase
- Phase 2a
- Women with symptomatic endometriosis
Historical Context
-
Reported Q2 results alongside SkinJect and Teverelix regulatory and clinical program progress
-
FDA authorized the NDA-enabling registrational Phase 2b SKNJCT-005 Gorlin Syndrome study
-
FDA feedback and IRB approval supported the optimized Phase 2 acute urinary retention study
-
UAE authorization allowed the PRECISION-E2 Phase 2a endometriosis study to proceed
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
antibody-drug conjugate technical
investigational new drug regulatory
orphan drug designation regulatory
rare pediatric disease regulatory
gnrh antagonist medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications
PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company, anchored by the advancement of CD228V, a second-generation CD228-targeted antibody-drug conjugate (“ADC”), while pursuing capital-efficient strategic partnerships to advance clinical development opportunities across its SkinJect® and Teverelix® Programs.
CD228V now represents the principal strategic priority for Medicus, with initial development concentrated on establishing clinical proof-of-concept in a carefully selected tumor population, supported by an integrated clinical and translational strategy. Based on the existing biological, translational and clinical foundation, melanoma represents a compelling initial development opportunity, particularly in patients with relapsed or refractory disease.
The addition of CD228V represents a paradigm shift in Medicus’ clinical development portfolio and establishes precision oncology as a central component of the Company’s strategy.
CD228V is a second-generation ADC targeting melanotransferrin/CD228 in solid tumors. The program is supported by an active U.S. Investigational New Drug (IND), a first-in-human Phase 1 clinical study (NCT06799533), and substantial prior scientific, translational, and clinical development.
The Company believes successful demonstration of clinical proof-of-concept in melanoma, supported by an integrated translational and biomarker strategy, could provide an important foundation for subsequent development in other CD228-expressing solid tumors.
At the same time, Medicus is sharpening the development strategies for its two other therapeutic programs.
For SkinJect®, the Company believes the strongest risk-adjusted opportunity lies in Gorlin syndrome rather than broad sporadic/nodular Basal Cell Carcinoma (BCC) lesions. FDA has authorized initiation of SKNJCT-005, the Company’s NDA-enabling registrational Phase 2b study in patients with Gorlin syndrome presenting with multiple BCCs. Gorlin syndrome is a rare autosomal dominant disease in which patients can develop numerous BCC lesions throughout their lifetime, frequently requiring repeated surgical or other lesion-directed procedures.
The Company believes concentrating SkinJect® development on Gorlin syndrome could provide several potential strategic advantages beyond the more broadly competitive sporadic BCC market, which could include approvals for Orphan Drug Designation (“ODD”) and Rare Pediatric Disease (“RPD”) designation by the FDA as well as favorable rare-disease-anchored net pricing.
For Teverelix®, Medicus intends to prioritize the optimized approximately 126-patient Phase 2 acute urinary retention (“AUR”) program and PRECISION-E2, the Phase 2a study in women with symptomatic endometriosis, while continuing to advance the scientific and strategic positioning of Teverelix® in advanced prostate cancer (“APC”) through potential partnerships.
The Company believes this focused portfolio strategy provides multiple opportunities for meaningful clinical and shareholder value creation while enabling the Company to concentrate capital on programs with the most compelling near-term risk-adjusted potential.
Management Commentary:
“Medicus has undergone a significant transformation this year,” stated Dr. Raza Bokhari, Executive Chairman & CEO of Medicus. “Our objective is increasingly clear. We are concentrating our capital and organizational resources on programs where we believe focused clinical development and execution may create the greatest value and improve patient outcomes, while using strategic partnerships and other capital-efficient structures to preserve and unlock the potential value of other programs. We believe that our primary focus on precision oncology substantially enhances our long-term growth profile and positions the Company to participate in one of the most dynamic sectors of biotechnology.”
For further information contact:
Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com
Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com
About Medicus Pharma Ltd.
Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents.
The Company’s current therapeutic assets are:
CD228V ADC, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform, directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.
SkinJect®, an investigational novel localized immuno-oncology precision product focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) lesions in Gorlin Syndrome patients, a rare autosomal dominant disease also called nevoid BCC syndrome.
Teverelix®, an investigational next-generation GnRH antagonist, is being developed as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients, patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate and symptomatic endometriosis.
Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes "forward-looking statements" or “forward-looking information” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, “forward-looking statements”). "Forward-looking statements" are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company’s co-development with Pfizer with respect to CD228V and the anticipated benefits thereof, the Company’s plans and expectations relating to the development, manufacture and commercialization of CD228V across human therapeutic indications, the timing, design, conduct and results of any future clinical study of CD228V, including the Company’s plans to initiate clinical development in melanoma, the Company’s intention to focus initial development on melanoma, with potential subsequent development in squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and esophageal cancer, and to evaluate additional indications and lines of therapy; the potential market opportunities related to CD228V, SkinJect® and Teverelix® and the Company’s other therapeutic assets, and the development, advancement and commercialization thereof; the Company’s prioritization of CD228V and its related strategic and capital-allocation decisions, including its evaluation of strategic, partnership and other funding opportunities; the initiation, timing, design, conduct and results of the SKNJCT-005 registrational Phase 2b study and whether the results of that study will be sufficient to support the submission of a new drug application; the initiation, timing, design, conduct and results of the Company’s approximately 126-patient Phase 2 study in acute urinary retention and of PRECISION-E2, the Phase 2a study in women with symptomatic endometriosis; whether the FDA will grant Orphan Drug Designation or Rare Pediatric Disease designation for SkinJect® in Gorlin Syndrome and the benefits of any such designation, if granted; the potential pricing of, and reimbursement for, SkinJect®, if approved; the Company’s expectations regarding potential clinical and shareholder value creation and the sufficiency and allocation of its capital resources; and the Company’s ability to identify, negotiate and consummate strategic partnerships for SkinJect® and for Teverelix® in advanced prostate cancer on acceptable terms or at all. Forward-looking statements are often, but not always, identified by the use of such terms as "may", “on track”, “aim”, "might", "will", "will likely result", “could,” “designed,” "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2025, and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
FAQ
What is CD228V and which tumors is Medicus initially targeting?
CD228V is a second-generation antibody-drug conjugate that uses Pfizer’s vedotin linker-payload platform and targets melanotransferrin (CD228), a cell-surface protein expressed in several solid tumor types. Medicus plans to concentrate initial development on melanoma, particularly in patients with relapsed or refractory disease, with the goal of generating clinical proof-of-concept to support potential expansion into other CD228-expressing tumors.
How is Medicus changing the development strategy for SkinJect?
For SkinJect®, Medicus plans to focus on Gorlin syndrome rather than broader sporadic or nodular basal cell carcinoma. The Company believes Gorlin syndrome offers a stronger risk-adjusted opportunity and could support applications for Orphan Drug Designation and Rare Pediatric Disease designation, as well as rare-disease-oriented pricing, if SkinJect is successfully developed and approved.
Which clinical studies are planned for Teverelix under the new strategy?
Medicus intends to prioritize an optimized, approximately 126-patient Phase 2 study in acute urinary retention and the PRECISION-E2 Phase 2a study in women with symptomatic endometriosis for Teverelix®. The Company also plans to continue advancing the scientific and strategic positioning of Teverelix in advanced prostate cancer through potential partnerships.
What is Medicus’ stated objective with this portfolio refocus?
Management stated that the objective is to concentrate capital and organizational resources on programs where focused clinical development and execution may create the greatest value and improve patient outcomes, while using partnerships and other capital-efficient structures to preserve and potentially unlock value in other programs.